- Home
- NVA vs CTMX Comparison
NVA vs CTMX Comparison
Compare NVA & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVA
- CTMX
- Stock Information
- Founded
- NVA 1987
- CTMX 2008
- Country
- NVA Australia
- CTMX United States
- Employees
- NVA N/A
- CTMX N/A
- Industry
- NVA
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- NVA
- CTMX Health Care
- Exchange
- NVA NYSE
- CTMX Nasdaq
- Market Cap
- NVA 68.3M
- CTMX 60.7M
- IPO Year
- NVA N/A
- CTMX 2015
- Fundamental
- Price
- NVA $13.80
- CTMX $2.51
- Analyst Decision
- NVA
- CTMX Strong Buy
- Analyst Count
- NVA 0
- CTMX 2
- Target Price
- NVA N/A
- CTMX $5.00
- AVG Volume (30 Days)
- NVA 14.8K
- CTMX 11.5M
- Earning Date
- NVA 01-01-0001
- CTMX 05-12-2025
- Dividend Yield
- NVA N/A
- CTMX N/A
- EPS Growth
- NVA N/A
- CTMX 128.27
- EPS
- NVA N/A
- CTMX 0.49
- Revenue
- NVA N/A
- CTMX $147,557,000.00
- Revenue This Year
- NVA N/A
- CTMX N/A
- Revenue Next Year
- NVA N/A
- CTMX N/A
- P/E Ratio
- NVA N/A
- CTMX $5.18
- Revenue Growth
- NVA N/A
- CTMX 23.81
- 52 Week Low
- NVA $4.35
- CTMX $0.40
- 52 Week High
- NVA $19.00
- CTMX $2.82
- Technical
- Relative Strength Index (RSI)
- NVA N/A
- CTMX 69.95
- Support Level
- NVA N/A
- CTMX $1.97
- Resistance Level
- NVA N/A
- CTMX $2.64
- Average True Range (ATR)
- NVA 0.00
- CTMX 0.32
- MACD
- NVA 0.00
- CTMX 0.03
- Stochastic Oscillator
- NVA 0.00
- CTMX 67.71
About NVA NOVA MINERALS LTD SPON ADS EACH REP 60 ORD
Nova Minerals Ltd is a Gold, Antimony and Critical Minerals exploration and development company focused on advancing the Estelle Project. It includes projects such as Estelle Gold and Critical Minerals Project, RPM, Korbel, Train and Stoney. It operates in one segment which is exploration of minerals and two geographical areas, being Australia and United States, where Australia derives maximum revenue.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.